Entrectinib price in 2025

Entrectinib (Entrectinib) is a new oral multi-target tyrosine kinase inhibitor that mainly targets tumor cells positive for ROS1, NTRK and ALK gene fusion. Its mechanism of action is to inhibit the kinase activity of these abnormal fusion genes, thereby blocking the tumor cell proliferation signaling pathway and achieving anti-tumor effects. Entrectinib is indicated for the treatment of solid tumors in adult and pediatric patients, especially those driven by ROS1-positive non-small cell lung cancer and NTRK gene fusions. This drug is part of precision targeted therapy and is suitable for patients whose targets have been confirmed by molecular testing. It provides an individualized treatment plan that is unmatched by traditional chemotherapy.

In the domestic market, entrectinib has been approved for marketing and has been included in the scope of medical insurance reimbursement. Eligible patients can obtain the drug through medical insurance channels in hospitals, thus reducing their personal financial burden. Common specifications include100mg with 30 capsules and 200mg with 90 capsules. The price of each box is about more than 20,000 yuan. Prices in overseas markets are significantly higher. For example, the European version of 200mg*90 tablets of the original drug may cost more than 40,000 yuan per box, and the price is greatly affected by exchange rate fluctuations.

At the same time, generic drugs are also available in overseas markets, providing patients with affordable options. For example, the 100mg*60-capsule generic drug produced by a Lao pharmaceutical factory costs more than 1,000 yuan per box, and its ingredients are similar to the original drug. The emergence of generic drugs not only reduces the financial pressure of long-term treatment on patients, but also provides wider accessibility to patients in developing countries. Overall, entrectinib has obvious price differences in the global market, but with its clear target and good efficacy, it is still an important targeted treatment option for patients with ROS1 or NTRK fusion-positive patients.

Domestic patients can purchase original drugs through medical insurance, which can not only ensure the quality and efficacy of the drugs, but also reduce the financial burden; overseas patients can choose original drugs or generic drugs with reliable quality according to the actual situation. In clinical application, patients should choose the appropriate dosage and medication regimen according to the genetic test results and condition under the guidance of a doctor.

Reference materials:https://www.roche.com/products/rozlytrek